Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...

Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Start 7-day free trial → Log in

Paridiprubart · EB-05

Other · developed by Edesa Biotech

Phase 2 Most advanced trial

EDSA Developer

1 Registered trials

What is Paridiprubart?

Paridiprubart (also coded EB-05 or EB05) is an investigational agent given as a single intravenous dose of 15 mg/kg, up to a maximum of 1440 mg. It is studied in acute respiratory distress syndrome (ARDS).

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as: EB-05
Drug type: Other
Therapy area: Respiratory
Developer: Edesa Biotech Inc. (EDSA)
FDA status: Investigational, not approved in the US. Most advanced trial: Phase 2
UNII: 4LH8QAS0LR

🧪 Clinical trials

Trial	Phase	Condition	Status	Sponsor
NCT06703073	Phase 2	Acute Respiratory Distress Syndrome (ARDS)	Recruiting	EDSA

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Acute Respiratory Distress SyndromeAcute Respiratory Distress Syndrome (ARDS)ARDSARDS (Acute Respiratory Distress Syndrome)

More from Edesa Biotech

EB01 Phase 2

Sources

ClinicalTrials.gov NCT06703073

Updated Oct 11, 2026. Something wrong or missing? Report it on the EDSA page.

Follow EDSA, the company behind Paridiprubart

See EDSA's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

EDSA catalysts and pipeline →

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z